{"id":"NCT01570829","sponsor":"Materia Medica Holding","briefTitle":"Clinical Trial of Safety and Efficacy of New Dosage Schedule for Dietressa Drug in Treatment of Obese Patients","officialTitle":"Multicentric Double-blind Placebo-controlled Randomized Parallel-group Clinical Trial of Safety and Efficacy of New Dosage Schedule for Dietressa Drug in Treatment of Obese Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-12","primaryCompletion":"2013-06","completion":"2013-06","firstPosted":"2012-04-04","resultsPosted":"2021-08-26","lastUpdate":"2021-08-26"},"enrollment":331,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Obesity"],"interventions":[{"type":"DRUG","name":"Dietressa","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Dietressa","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"* To assess safety of Dietressa in the dose of 6 tablets daily within 24 weeks in treatment of obese patients (BMI 35,0-39,9 kg/m2).\n* To assess clinical efficacy of Dietressa in the dose of 6 tablets daily after 24 weeks of therapy in reducing body weight in obese patients (BMI 35,0-39,9 kg/m2).","primaryOutcome":{"measure":"Percentage of Patients With at Least 5% Weight Loss.","timeFrame":"24 weeks","effectByArm":[{"arm":"Dietressa","deltaMin":80,"sd":null},{"arm":"Placebo","deltaMin":62,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0352"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":17,"countries":["Russia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":164},"commonTop":["Increased anxiety","Depression","Depression, worsening","Viral respiratory tract infection","Increased appetite"]}}